advertising
-
1.
Gupta, AK and LE Lynch. :Onychomycosis: review of recurrence rates, poor prognostic factors, and strategies to prevent disease recurrence. .Cutis 74::10. ,2004. .
-
2.
Scher, RK and R Baran. :Onychomycosis in clinical practice: factors contributing to recurrence. .Br J Dermatol 149( Suppl 65:):5. ,2003. .
-
3.
US Food and Drug Administration :510(k) Database. .Summary K093547: PinPointe FootLaser, PinPointe USA, Inc .Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf9/K093547.pdf. .Accessed October 3, 2011.
-
4.
Australian Register of Therapeutic Goods: Public Summary 163176 .Available at: https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=163176&agid=(PrintDetailsPublic)&actionid=1. .Accessed November 1, 2011.
-
5.
Harris, DM, BA McDowell, and J Stristower. :Laser treatment for toenail fungus. .Proc of SPIE 71610::1. ,2009. .
-
6.
US Food and Drug Administration :510(k) Database. .Summary K103626: Cutera GenesisPlus Laser System, Cutera, Inc .Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf10/K103626.pdf. .Accessed October 3, 2011.
-
7.
Weiss, D . :3 month clinical results using sub-millisecond 1064nm Nd:YAG laser for the treatment of onychomycosis .Available at: http://conejofeet.com/wp-content/uploads/2011/06/David-Weiss-DPM-report.pdf. .Accessed November 2011.
-
8.
US Food and Drug Administration :510(k) Database. .Summary K103338: CoolTouch VARIA, New Star Lasers, Inc .Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf6/K060966.pdf. .Accessed November 1, 2011.
-
9.
US Food and Drug Administration :510(k) Database. .Summary K110370. Q-Clear, Light Age, Inc .Available: http://www.accessdata.fda.gov/cdrh_docs/pdf11/K110370.pdf. .Accessed November 2011.
-
10.
Drugs@FDA Database :Lamisil Product Label, Novartis .Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020539s018lbl.pdf. .Accessed October 2011.
-
11.
Drugs@FDA Database :Sporanox Product Label, Janssen Pharms .Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020083s046lbl.pdf. .Accessed November 1, 2011.
-
12.
Drugs@FDA Database :Penlac Product Label, Sanofi Aventis .Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21022s004lbl.pdf. .Accessed November 1, 2011.
Newly Approved Laser Systems for Onychomycosis
Mediprobe Research Inc, London, Ontario, Canada.
Search for other papers by Aditya K. Gupta in
Current site
Google Scholar
PubMed
Search for other papers by Fiona Simpson in
Current site
Google Scholar
PubMed
Laser systems are a new treatment area for onychomycosis. As of January 2012, the US Food and Drug Administration (FDA) has approved four laser systems for the “temporary increase of clear nail in onychomycosis.” The FDA has approved these devices on the basis of “substantial equivalence” to predicate devices with similar technical specifications and applications. Laser therapy appears to be a promising alternative to traditional pharmacotherapy, but these systems have been tested in only limited clinical trials; therefore, it is not possible to compare their efficacy to the oral and topical drugs currently used in the treatment of onychomycosis. (J Am Podiatr Med Assoc 102 (5): 428-430, 2012)
advertising
